Table 1. Main characteristics of all studies included in the meta-analysis.
| First author [References] | Year | Country | Cancer | Case number | Tumor stage (I/II/III/IV) | Follow-up (months) | Highexpression n (%) | Detected method | Cut-off value | Multivariate analysis | HRs provided from | Outcome measures |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LIU[11] | 2014 | Japan | Cervical | 102 | 73/29(I-IIA/IIB-TV) | 4.8-169 | 71 (69.6%) | IHC | NR | yes | Report | OS/DFS |
| Liang[12] | 2014 | China | Colorectal | 185 | 66/119(I–II/III–IV) | Over60 | 117(63.2%) | IHC | IRS≥4 | yes | Report | OS/DFS |
| Chen[16] | 2011 | China | ESC | 112 | 13/63/20/16 | Longest 111 | 66(58.9%) | IHC | H-score>160 | yes | Report | OS |
| Wang[27] | 2015 | China | ESC | 66 | 43/23(I–II/III–IV) | Over60 | 48(72.7%) | IHC | IRS≥4 | no | SC | OS |
| Arigami[15] | 2011 | Japan | Gastric | 120 | 62/58(I–II/III–IV) | Median 40 | 31(25.8%) | IHC | Moderate staining | yes | Report | OS |
| Jiang[13] | 2010 | China | Gastric | 156 | 14/22/102/18 | Over60 | 70(44.9%) | IHC | IRS≥9 | yes | SC | OS/DFS |
| Geng[26] | 2015 | China | Gastric | 100 | 40/60(I–II/III–IV) | Over60 | 71(71%) | IHC | IRS≥3 | yes | Report | OS |
| Maskey[24] | 2014 | China | Gastric | 56 | 12/44(I–II/III–IV) | 12-52 | 12 (21.4%) | IHC | IRS≥9 | no | SC | OS |
| Quandt[18] | 2011 | Germany | Melanoma | 29 | 26/3(III/IV) | Over60 | 21(72.4%) | IHC | IRS≥9 | no | SC | OS |
| Li[19] | 2013 | China | NSCLC | 49 | 13/29/7(I/II/III) | Over60 | 20 (40.8%) | IHC | IRS≥9 | yes | SC | OS |
| Dong[25] | 2015 | China | Osteosarcoma | 104 | 62/42(I–II/III) | Over60 | 73(70.19%) | IHC | IRS≥4 | yes | Report | OS |
| Simon[14] | 2007 | Italy | Ovarian | 233 | NR | Over60 | 141(60.5%) | ELISA | protein>426 pg/mg | no | SC | OS |
| Chen[22] | 2014 | China | Pancreatic | 63 | NR | 1-33 | 31(49.2%) | IHC | >30% of cells stained | no | SC | OS |
| Tsiaousidou[20] | 2013 | Greece | Pancreatic | 41 | 4/35/2(I/II/III) | 2-31 | 16(39.0%) | IHC | >10% of cells stained | yes | Report | OS |
| Zang[28] | 2007 | America | Prostate | 823 | NR | Median 84 | 120(15%) | IHC | IRS ≥3 | no | Report | DFS |
| Zhu[21] | 2013 | China | Thyroid | 64 | 30/34(I/II,III,IV) | 1-50 | 46 (71.9%) | IHC | IRS >6 | no | SC | OS |
| Fan[23] | 2014 | China | UCC | 62 | 11/51(Superficial/Invasive) | Over60 | 47(75.8%) | IHC | IRS≥4 | yes | Report | OS |
| Jung[17] | 2011 | Korea | RCC | 102 | NR | 6-84 | 18(17.6%) | IHC | >10% of cells stained | yes | SC | DFS |
ESC: esophageal squamous cell; NSCLC = non-small cell lung cancer; UCC: urothelial cell cancer; RCC:renal cell cancer; ELISA: enzyme-linked immunoabsorbent assay; IHC: immunohistochemistry; OS = overall survival; DFS = disease-free survival; NR: not report; SC: survival curve; IRS: immunoreactivity score.